Background: Abnormalities in the cyclic adenosine monophosphate (cAMP)-dependent phosphorylation system have been recently reported in patients with bipolar disorder. We evaluated the immunoreactivity of the regulatory and catalytic subunits of cAMP-dependent protein kinase (protein kinase A) and 1 of its substrates, Rap1, in platelets from untreated euthymic, manic, and depressed patients with bipolar disorder and healthy subjects.
different among groups (PϽ.001), with higher values in untreated depressed and manic patients with bipolar disorder compared with untreated euthymic patients with bipolar disorder and healthy subjects. No significant differences were found in the immunolabeling of the regulatory subunits (type I and type II) of cAMP-dependent protein kinase. The immunolabeling of Rap1 was significantly higher (PϽ.001) in untreated euthymic, depressed, and manic patients than in healthy persons.
Conclusions: Levels of Rap1 and the catalytic subunit of cAMP-dependent protein kinase are altered in the platelets of bipolar patients. These findings may provide clues toward understanding the involvement of cAMP signaling in the pathogenesis of bipolar disorder. Psychiatry. 1999; 56:248-253 B IPOLAR DISORDER is a common illness affecting approximately 1% of the population. 1 The biochemical mechanisms underlying the pathogenesis of this disorder remain to be clearly established. In recent years, however, numerous studies [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] have reported abnormalities in components of cyclic adenosine monophosphate (cAMP) signaling such as G proteins in postmortem brain and peripheral cells of patients with bipolar disorder.
Arch Gen
The cAMP-dependent protein kinase (protein kinase A [PKA] ) is a central component of cAMP signaling cascade because, with few exceptions, the intracellular events mediated by cAMP occur through its activation. [13] [14] [15] [16] As shown in Figure 1 , the PKA holoenzyme is organized as an inactive tetrameric complex composed of a regulatory subunit dimer and 2 monomeric catalytic subunits. The binding of cAMP to a regulatory subunit dimer results in the release and concomitant activation of the catalytic moieties, which in turn are able to phosphorylate specific substrate proteins, thereby regulating a great variety of cellular functions. [13] [14] [15] [16] Preclinical studies [17] [18] [19] [20] [21] [22] have shown that the binding of cAMP to regulatory subunits and the activity of PKA are altered after the administration of antidepressant medications and lithium salts. Furthermore, alterations in the levels of PKA have been reported 22 after lithium treatment. Changes in either the phosphorylation state or the levels of some cAMP-dependent phosphoproteins were also reported 20, [23] [24] [25] [26] [27] [28] [29] following treatment with these medications.
Data from clinical investigations suggest disturbances of the cAMP-dependent phosphorylation system in patients with bipolar disorder. In a preliminary study, 30 the cAMP-stimulated phosphorylation of a low-molecular-weight platelet protein was shown to be significantly higher in untreated euthymic patients with bipolar disorder than in controls. These results were subsequently confirmed, 31, 32 and the phosphoprotein was recognized as Rap1, 33 a small guanosine triphosphatebinding protein belonging to the ras fam-ily. In addition, abnormalities of the cAMP-binding activity have been reported 34 in the postmortem brain of subjects with bipolar disorder.
These findings suggest that disturbances of certain components of the cAMP-dependent phosphorylation system may contribute to the pathogenesis of bipolar disorder. Whether these abnormalities might be mirrored by changes in the levels of such components and linked to the mood states of patients with bipolar disorder remains to be established. These latter concepts define the framework of the present study, in which we assessed the levels of PKA and those of Rap1 in platelets from untreated euthymic, depressed, or manic patients with bipolar disorder and healthy subjects. Furthermore, in all collected specimens, we assessed the immunolabeling of actin, a cytoskeletal protein used as an internal control.
RESULTS

Figure 2
illustrates representative immunoblots of PKA subunits, Rap1, and actin immunoreactivities in total platelet proteins from untreated patients with bipolar disorder in euthymia, depression, or mania and from healthy subjects.
The monoclonal antibodies against the regulatory (type I or type II) or the catalytic subunits of PKA revealed the presence of major platelet protein bands migrating with apparent molecular masses of 49, 52, and 40 kd, respectively. The anti-Rap1 antibody recognized a single band with an apparent molecular mass of 21 kd and the antiactin antibody a single band with an apparent molecular mass of 42 kd. Quantitation of immunoblots was obtained through densitometric scanning of autoradiographs. Data were then normalized and analyzed as described in the "Statistical Analysis" subsection of the "Subjects and Methods" section. The Table summarizes the results obtained in each group of untreated patients with bipolar disorder and healthy subjects.
The analysis of variance revealed no significant difference in the levels of regulatory subunit type I (F 3,142 = 0.77; P = .51) or type II (F 3,162 = 0.24; P = .86) of PKA in platelets from the 4 groups (Table) . Significant differences were found in the levels of the catalytic subunit of the enzyme (F 3,160 = 15.57; PϽ.001). Post hoc comparisons showed that during illness episodes, patients with bipolar disorder had about 11% and 16% greater immunolabeling of catalytic subunit than euthymic patients with bipolar disorder and controls, respectively: manic patients vs euthymic patients, P = .003; manic patients vs control subjects, PϽ.001; depressed patients vs euthymic patients, PϽ.001; and depressed patients vs controls, PϽ.001. No differences were found when compar-
SUBJECTS AND METHODS
SUBJECTS
After providing written informed consent, 112 patients (60 men and 52 women; age, 37.24 ± 9.92 [mean ± SD] years) and 62 age-and sex-comparable healthy volunteers (36 men and 26 women; age, 40.33 ± 12.52 years) were included in this study. None of the subjects were part of previous studies. All patients, recruited at the Mood Disorders Clinical and Research Unit, San Raffaele Hospital, Milan, Italy, met the full criteria for bipolar I disorder according to the DSM-IV. 35 Those with a history of important acute or chronic medical illness or alcohol or psychotropic drug abuse were excluded. The diagnosis was assessed by clinical interview. Clinical information was collected directly from each patient and from at least 1 close relative as a coinformant. Any definitive documentation-eg, discharge summaries of prior hospital admissions for episodes of illness-that could be obtained were also considered in assessing the diagnosis. Medical health was documented by the medical history, physical examination, electrocardiography, blood and serum chemical analyses (including hepatic and renal profiles), and thyroid function tests.
The group with bipolar disorder comprised 52 outpatients in euthymic condition for at least 3 months before entering the study (a score of Յ8 on the 21-item Hamilton Depression Rating Scale, 36 and a score of Յ9 on the Young Mania Rating Scale 37 ), 29 inpatients with bipolar disorder with a depressive episode (score, Ͼ21 on the Hamilton Depression Rating Scale), and 31 inpatients with bipolar disorder with a manic episode (score, Ͼ21 on the Young Mania Rating Scale). The mean ± SD age of the 52 euthymic patients was 39.2 ± 12.5 years; of the 29 depressed patients, 41.9 ± 11.3 years; and of the 31 manic patients, 40.6 ± 13.8 years. The ages at onset were 29.3 ± 8.2 years, 29.1 ± 8.2 years, and 28.6 ± 8.9 years, respectively. The mean ± SD number of previous episodes was 3.5 ± 2.0 in euthymic patients, 4.2 ± 2.3 in depressed patients, and 3.3 ± 2.1 in manic patients. The sex distribution (male:female) in the 3 groups was 35:17, 16:13, and 9:22, respectively.
All patients had been medication free for at least 1 month before blood specimens were drawn. In particular, most patients (58%) had never taken lithium salts: 31 (59.6%) of 52 euthymic patients, 17 (58.6%) of 29 depressed patients, and 17 (54.8%) of 31 manic patients. The remaining patients had been treated with lithium only during previous manic episodes that occurred at least 1 year before entering the study and never as long-term therapy. Other mood-stabilizing agents used to treat previous episodes were carbamazepine in 20 (17.9%) of 112 patients and valproate sodium in 7 (6.2%) of 112 patients.
The comparison group included 62 consenting volunteers recruited from the staff of our hospital, who had no personal or familial history of mental disorders, alcoholism, or drug abuse and no active medical problems, as determined by clinical interview. To exclude the presence of a personal or familial history of mental disorders, the proband and, when possible, other members of the proband's family or social group were interviewed. Information regarding first-and seconddegree relatives was obtained for each subject.
PLATELET ISOLATION AND IMMUNOBLOT ANALYSIS
A morning blood specimen (50 mL) was obtained from all subjects by venipuncture and placed in tubes containing Continued on next page ing manic vs depressed patients and euthymic patients vs controls (Table) . The levels of the platelet Rap1 immunoreactivity from all collected specimens are shown in the Table. As determined by the analysis of variance, the immunolabeling of Rap1 was significantly different among groups (F 3,170 = 34.47; PϽ.001). Post hoc comparisons showed about a 20% significantly higher immunolabeling of Rap1 in euthymic, depressed, and manic patients than in healthy subjects (PϽ.001). No differences were found among patients with bipolar disorder in different mood states (Table) .
To test whether nonspecific effects could occur in our experimental conditions, immunostaining for the cytoskeletal protein actin (Figure 2 ) was performed in all collected specimens. As shown in the Table, the analysis of the immunoblots revealed no statistical difference in actin immunoreactivity among the 4 groups (F 3,170 = 0.83; P = .47).
COMMENT
Components of the cAMP-dependent phosphorylation system are altered in platelets from patients with bipolar disorder. More specifically, the levels of Rap1 were significantly higher in euthymic, depressed, and manic patients with bipolar disorder than in healthy subjects.
Furthermore, only the levels of catalytic subunits of PKA were significantly higher in depressed and manic patients than in euthymic patients and controls. Overall, these data suggest that altered levels of Rap1 observed in the whole sample of patients with bipolar disorder could be considered a state-independent biochemical abnormality, whereas those of PKA observed only in depressed and manic patients could be considered a staterelated abnormality.
The main limitation of our findings is that they come from platelets that are exposed to a potentially different neurohormonal environment than that of brain tissue. Transposing platelet findings to those that might be found only in a subset of neurons in the brain in this disorder can be difficult. Furthermore, it is not possible to exclude the role of a previous exposure to psychotropic drugs in producing these changes, even though patients were apparently drug free for at least 1 month. Taking into account these limitations, our data complement previous reports [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [30] [31] [32] 39, 40 demonstrating alterations in the cAMP signaling in patients with affective disorders.
The observed abnormalities are unlikely to be the result of a general alteration in platelet proteins because the immunolabeling of both types of regulatory subunits and of actin, the protein used as an internal control, showed no change among groups. sodium citrate (3.8%) as an anticoagulant. Platelets were isolated from the fresh blood specimen as previously described. 30, 31 Pellets were then washed 3 times with icecold Tris hydrochloride isotonic buffer and then frozen at −80°C until subsequent use. On the day of the assay, platelets were homogenized by sonication with two 15-second pulses in ice-cold Tris hydrochloride buffer (10 mmol/L) containing egtazic acid (1 mmol/L), ethylenediaminetetraacetic acid (1 mmol/L), dithiothreitol (1 mmol/L), pepstatin (2 mg/mL), aprotinin (50 U/mL), and phenylmethylsulfonyl fluoride (0.1 mmol/L), pH 7.4. The platelets were prepared and then analyzed by personnel unaware of the diagnosis.
Protein concentrations were determined according to the method of Bradford. 38 The linearity of the platelet protein concentration for the Western blotting experiments was ascertained by resolving selected quantities-between 2 and 25 µg-of proteins. The relationship between the total amount of proteins loaded into the gels and the integration of area ϫ optical density was linear within 2 to 15 µg of protein range.
Whole-platelet homogenates from each subject were solubilized in denaturing buffer and boiled for 2 minutes. Aliquots with equal amounts of proteins (5 µg) were loaded on 12% polyacrylamide gels and subjected to 1-dimensional electrophoresis (sodium dodecyl sulfate polyacrylamide gel electrophoresis). Patients' specimens were always run in duplicate or triplicate on the same gel with those of their respective controls. Proteins, thus resolved in bands, were electrophoretically transferred onto Hybond polyvinylidene difluoride membrane (Amersham International, Buckinghamshire, England) for 90 minutes at 100 V. Blots were then preincubated for 1 hour in Tris buffered saline-Tween 20 buffer, pH 7.6 (Tris hydrochloride, 25 mmol/L; sodium chloride, 137 mmol/L; and 0.1% Tween 20), containing 1% bovine serum albumin (blocking buffer). All incubations were performed at room temperature. After a thorough washing with TBS-T, the blots were incubated in blocking buffer for 90 minutes with monoclonal antibodies against the regulatory type I (Transduction Laboratories, Lexington, Ky; dilution 1:500), the regulatory type II (Biomol, PlymouthMeeting,Pa;dilution1:500),andthecatalytic(Transduction Laboratories; dilution 1:500) subunits of PKA, Rap1 (Transduction Laboratories; dilution 1:2500), and actin (clone DC40, Sigma-Aldrich Corp, St Louis, Mo; dilution 1:3500). After being extensively washed with TBS-T, the blots were incubated with the second antibody, horseradish peroxidaselinked antimouse (Sigma-Aldrich Corp; dilution 1:1000), in blocking buffer for 1 hour. The labeled blots were then washed withTBS-T,andimmunoreactivitywasdetectedwiththeWestern blot detection system (Enhanced Chemiluminescent, Amersham International), followed by exposure to film. Quantitation of the immunoblots was performed by densitometric scanning of the autoradiograms using an image analysis system (National Institutes of Health Image, Version 1.47, Bethesda, Md). Not all patients and controls had assays for the various antibodies because a satisfactory amount of platelet proteins was not obtained for each subject.
An aliquot of pooled standard platelet proteins was run on 1 lane of every gel to minimize the interassay variation, as previously described. 6, 10 The optical density units obtained from each subject were normalized against those from a pooled platelet standard.
STATISTICAL ANALYSIS
Data were analyzed using a 1-way analysis of variance (2-tailed), followed by Newman-Keuls post hoc comparison tests. Results are expressed as mean ± SD. The level of significance was PϽ.05.
Previous studies [30] [31] [32] have reported higher cAMPdependent phosphorylation of Rap1 in platelets of untreated euthymic patients with bipolar disorder. Our data showing higher Rap1 and unvaried PKA levels in euthymic patients with bipolar disorder suggest that the abnormal phosphorylation in the former can be attributed to the increase in its own levels. This is also supported by the fact that the 20% increment in Rap1 immunoreactivity is comparable to that previously reported [30] [31] [32] in the cAMP-stimulated phosphorylation of this protein.
Considering the lack of evidence with respect to protein phosphorylation in patients with bipolar disorder in different mood states, further studies are needed to clarify the relationship between the levels of Rap1 and catalytic subunits observed in depressed and manic patients.
Bearing in mind that lithium and antidepressant drugs have many dissimilar clinical effects and could affect components of cAMP signaling differently, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] 31, 41 it will be interesting to test whether these compounds could cause the levels of PKA and Rap1 in patients with bipolar disorder to return to normal.
Whether the results presented here are primary disease-related changes or reflect adaptive responses consequent to other dysfunctions in cell signaling is still unclear. It has been documented [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] that patients with bipolar disorder have disturbances in G proteins coupled to cAMP signaling, which may lead to dysfunctions in the cAMPdependent phosphorylation. Furthermore, keeping in mind the cross-talk between the signal transduction pathways, 42, 43 the observed modifications may be joined to disturbances in Ca 2+ signaling and the phosphoinositides cycle, including protein kinase C activity, which were found altered in patients with bipolar disorder. [44] [45] [46] [47] [48] [49] [50] [51] Rap1 is a small guanosine triphosphate-binding protein present in different tissues, including the brain. 52 Although its role remains to be fully elucidated, evidence indicates that Rap1 could be involved in cellular events, such as calcium mobilization, cytoskeleton organization, and phosphoinositides metabolism, most of which Figure 1 . Schematic representation of the cyclic adenosine monophosphate (cAMP) signaling pathway. In the absence of cAMP, protein kinase A exists as an inactive tetrameric complex composed of a dimer of regulatory subunits (R) joined by a disulfide bond (S) and 2 catalytic subunits (C). The binding of a neurotransmitter to the specific receptor activates the stimulatory G protein (Gs), which in turn activates adenylate cyclase (AC), an enzyme that catalyzes the production of cAMP from adenosine triphosphate (ATP). Protein kinase A is activated through a reaction during which cAMP binds R subunits, and the enzymatic complex subsequently dissociates into an R dimer and 2 free C subunits. Once released from the holoenzyme state, C moieties are able to phosphorylate many and specific substrate proteins, including Rap1. *Data are given as mean densitometric standardized units ± SD. †Controls, n = 43; euthymic patients, n = 47; depressed patients, n = 26; and manic patients, n = 30. ‡Controls, n = 55; euthymic patients, n = 51. §Controls, n = 54; euthymic patients, n = 50. PϽ.001 vs euthymic patients and PϽ.001 vs control subjects. ¶P = .003 vs euthymic patients and PϽ.001 vs control subjects. #PϽ.001 vs control subjects.
have been found to be also altered in patients with bipolar disorder. [44] [45] [46] [47] [48] [49] [50] [51] [53] [54] [55] [56] [57] More recently, Rap1 was found to be involved in the regulation of signal cascade coupled to neurotrophic factors. 58, 59 This is an intriguing finding considering recent data, 20, 27, 60 suggesting an involvement of neurotrophic factors in mood disorders.
At present, it is difficult to envisage the molecular mechanism(s) underlying the alterations of Rap1 and PKA. A recent study 61 demonstrated no structural or regulatory abnormalities in the gene encoding for the G protein stimulatory ␣ subunit, even if its levels were altered in patients with bipolar disorder. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] These findings suggest that alterations in the transcriptional, posttranscriptional, translational, or posttranslational processes that are known to regulate the levels of proteins should be taken into account.
CONCLUSIONS
Levels of Rap1 and the catalytic subunit of PKA are altered in platelets of patients with bipolar disorder. These findings may provide clues toward understanding the involvement of cAMP signaling in the pathogenesis of bipolar disorder.
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